NCT07193420View on ClinicalTrials.gov

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
GVHD - Graft-Versus-Host DiseaseHSCTHaploidentical Stem Cell Transplantation
Interventions
DRUG

Cyclophosphamide 35mg/kg/day

Cyclophosphamide will be administered intravenously (IV) post-HSCT at the experimental dose (70 mg/kg, divided into two doses of 35 mg/kg/day on days +3 and +4).

DRUG

Cyclophosphamide 50mg/kg/day

Cyclophosphamide will be administered intravenously (IV) post-HSCT at the standard dose (100 mg/kg, divided into two doses of 50 mg/kg/day on days +3 and +4).

Trial Locations (1)

75012

Saint Antoine Hospital - Hematology Department, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER